[64Cu]Cu-NOTA-Dara-F(ab′)2, which showed rapid and high tumour uptake at 2 h after injection (6.9 ± 1.2%ID/g) and peaked (9.5 ± 0.7%ID/g) at 12 h.226 Apart from the marketed drug daratumumab, the anti-CD38 mAb OKT10 is also used as a key component of the CD38-targeting antibody.227 The [211At]CD38 mAb has been proven to be an effective α-emitting radiolabelled mAb, leading to durable relief and prolonged patient survival (>150 days).228. This evidence concerns the gene CD38 and neoplasm.